The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences Inc. is gearing up for BIO2026, aiming to connect with key industry leaders and innovators in the field of precision genetic medicine.
The company is inviting those interested in next-generation SolidInside technologies to engage ahead of the event, emphasizing its commitment to advancing genetic medicine innovation and fostering partnerships that can accelerate progress in the sector.
Earlier this year, Solid Biosciences presented clinical insights for its SGT-003 gene therapy candidate at a leading Duchenne muscular dystrophy conference. The company also recently sponsored the Jett Foundation's 25th Anniversary Silver Soirée. These activities highlight ongoing engagement with both the research community and patient advocacy groups.